Eli Lilly CDR (CAD Hedged)

Strand Therapeutics closed a $153 million Series B funding round led by Kinnevik, with participation from major pharmaceutical companies including Eli Lilly, Amgen, and Regeneron Ventures.

Nxera Pharma has launched a broad proprietary pipeline targeting obesity and chronic weight management, led by a new oral small molecule GLP-1 agonist program.

Swiss generic manufacturer Sandoz plans to launch unbranded semaglutide weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents expire next year.

Frazier Healthcare Partners has successfully closed a $1.3 billion venture capital fund specifically targeting early-stage biotechnology companies and startup creation.

AbbVie's Rinvoq demonstrated significant efficacy in a Phase III trial for alopecia areata, with 47.1% of patients achieving 90% or more scalp hair coverage on the 30mg dose versus 1.4% on placebo.

Tirzepatide showed noninferiority to dulaglutide for major adverse cardiovascular events in the SURPASS-CVOT trial, while reducing all-cause mortality by 16% in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

GSK's anti-TIM-3 monoclonal antibody cobolimab failed to improve overall survival in the Phase III COSTAR trial for advanced non-small cell lung cancer patients previously treated with immunotherapy.

Therini Bio has dosed the first patient in a Phase 1b trial of THN391, a first-in-class monoclonal antibody targeting fibrin-mediated neuroinflammation in Alzheimer's disease.

Roche announced plans to test Trontinemab, an experimental drug designed to delay or prevent Alzheimer's disease symptoms in at-risk individuals.

BioChaperone Lispro (THDB0206) demonstrated non-inferior HbA1c reduction compared to Humalog in a Phase 3 trial of 1,040 Chinese adults with Type 2 diabetes.